Back

LDL-c levels and clinical outcomes in acute myocardial infarction patients with prior ischemic stroke

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Clinical impact of lipid‑lowering strategies Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Kang-Yin Chen

2nd Hospital of Tianjin Medical University, Tianjin (China)

7 More presentations in this session

Presentation thumbnail
Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis
Professor C. Li (Nanjing, CN)
Abstract Slides
Presentation thumbnail
Comparative efficacy of APOC3- and ANGPTL3-targeted therapies in severe hypertriglyceridemia: a systematic review and network meta-analysis
Doctor G. Caldeira Gaelzer (Curitiba, BR)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides
Presentation thumbnail
Quantitative and qualitative lipid responses to lipid-lowering therapy and cardiovascular outcomes after percutaneous coronary intervention for acute myocardial infarction
Doctor K. Lee (Daejeon, KR)
Presentation thumbnail
Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD
Doctor M. Koren (Jacksonville, US)
Abstract Slides

Access the full session

Session thumbnail
Clinical impact of lipid‑lowering strategies

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
LDL-cholesterol levels post-acute coronary syndrome: 24-months variation
4 April 2025
thumbnail
Congress Presentation
Lipid target in stroke: biomarkers and targeted intervention
24 April 2026
thumbnail
Congress Presentation
Prognostic impact of beta-blockers in AMI patients with mid-range left ventricular ejection fraction
21 May 2023
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources